Ozan Verendağ

Ozan Verendağ

Auto-generated profile, based on publicly available information

Ozan Verendağ

Ege University School of Medicine

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2025 in Scottish Medical Journal
Verified
Journal Article
Closed access
ÖKÖzgür Kılınçarslan
Özgür Kılınçarslan
VSVolkan Sayur
Volkan Sayur
EGErkan Güler
Erkan Güler
RTRecep Temel
Recep Temel
ÖKÖzgün Cevdet Köse
Özgün Cevdet Köse
TSTaylan Özgür Sezer
Taylan Özgür Sezer
Background: Peritoneal carcinomatosis (PC) represents an advanced stage of intra-abdominal malignancies with poor prognosis. Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) offers promising outcomes in selected patients. This study evaluated survival and prognostic factors in patients undergoing CRS-HIPEC for malignancy-associated PC. Methods: A retrospective analysis was performed on 116 patients treated with CRS-HIPEC between 2015 and 2023. Data included demographics, tumor origin, peritoneal cancer index (PCI), completeness of cytoreduction (CC) score, complications, and survival outcomes. Kaplan–Meier and Cox regression analyses were used. Results: The mean age was 55.2 years; 61.2% were female. Common primary tumors were colorectal (34.5%), gastric (20.7%), ovarian (17.2%), and appendiceal (16.4%). Mean PCI was 11.9, and complete cytoreduction (CC-0) was achieved in 89.7%. Overall survival was highest in appendiceal (76.9 months) and lowest in gastric cancer (24.7 months). Median disease-free and overall survival were 36 and 43.9 months, respectively. Postoperative complications occurred in 31.8%; mortality was 5.17%. High PCI and incomplete cytoreduction were independently associated with worse survival. Conclusion: CRS-HIPEC provides encouraging survival in selected PC patients, especially with low PCI and complete cytoreduction. Careful patient selection remains key to optimizing outcomes.

29 June 2022 in Turkish Journal of Surgery
Verified
Journal Article
Open access
PDF file
OBOsman Bozbıyık
Osman Bozbıyık
CÇCemil Çalışkan
Cemil Çalışkan
ÖKÖzgün Köse
Özgün Köse
OVOzan Verendağ
Ozan Verendağ
BGBerk Göktepe
Berk Göktepe
MKMustafa Ali Korkut
Mustafa Ali Korkut
Objective: Currently, sphincter-saving procedures are increasingly performed in the treatment of low rectal cancers. This study aimed to evaluate the outcomes of patients who underwent intersphincteric resection. Material and Methods: This was a single-center, retrospective, cross-sectional study. We evaluated the electronic data files of 29 patients who had intersphincteric resections at our institute between 2008 and 2018. Bowel function outcomes were assessed prospectively using Wexner incontinence score. Histopathological, surgical and functional outcomes were analyzed. Results: Mean age of nine female and 20 male patients included in the study was 55.8 ± 12.8 (30-76) years. A tumor-free surgical margin was achieved in all patients. Anastomotic leakage was detected in two patients. Mean Wexner incontinence score of 20 patients who still had functional anastomosis was 8.35, whereas 65% of the patients (n= 13) had a good continence status. There was no relationship between the continence status and sex, tumor distance from anal verge, T stage, distal surgical margin, and lymph node involvement. Twenty-one patients underwent primary coloanal anastomosis and eight patients underwent two-stage coloanal anastomosis. Conclusion: In the treatment of distal rectal cancer, adequate oncological surgery and relatively acceptable functional outcomes can be obtained with intersphincteric resection technique in suitable patients.